Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Company Drug

Zai Lab’s Augtyro NDA Accepted by China’s NMPA for NTRK Fusion Solid Tumors

Fineline Cube Apr 22, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug...

Company Drug

Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder

Fineline Cube Apr 22, 2025

Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan’s Ministry of...

Company Deals

Dizal Pharma Secures RMB 1.796 Billion Private Placement to Advance R&D and Facilities

Fineline Cube Apr 22, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has completed a private placement, raising RMB 1.796...

Company Drug

Bio-Thera Solutions Gains NMPA Clinical Approval for BAT7111 in Advanced Solid Tumors

Fineline Cube Apr 22, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) has announced that it has received clinical approval from...

Company Drug

Ascentage Pharma’s Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion

Fineline Cube Apr 22, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that its two innovative drugs have been...

Company Drug

Gan & Lee’s GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes

Fineline Cube Apr 22, 2025

China’s Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial clearance...

Policy / Regulatory

China’s Medical Insurance Payment Reform Achieves Nationwide Coverage, Faces Challenges Ahead

Fineline Cube Apr 22, 2025

The first blue book on the reform of China’s medical insurance payment methods, titled “Report...

Company Drug

Regeneron’s Eylea HD Receives FDA Complete Response Letter Despite Priority Review

Fineline Cube Apr 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received a Complete Response Letter (CRL)...

Company Drug

Hengrui Gains NMPA Approval for Phase III Study of SHR-8068 in PD-L1 Negative NSCLC

Fineline Cube Apr 22, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical...

Company Drug

Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518

Fineline Cube Apr 22, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that it has received clearance from the...

Company Drug

Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial

Fineline Cube Apr 22, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated...

Company Deals

Shanghai Operation Robot Secures RMB 100 Million Series C Funding for AI-Driven Surgical Robot Development

Fineline Cube Apr 22, 2025

Shanghai-based medical robotics developer Operation Robot Co., Ltd. has reportedly raised close to RMB 100...

Company Deals

Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management

Fineline Cube Apr 22, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...

Company Drug

Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction

Fineline Cube Apr 22, 2025

China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...

Company Medical Device

Broncus Medical Secures NMPA Approval for BroncAblate in Lung Cancer Treatment

Fineline Cube Apr 22, 2025

Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung disease, announced...

Company Drug

Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871

Fineline Cube Apr 22, 2025

Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received...

Company Deals

Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China

Fineline Cube Apr 22, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has entered into a hospital-channel...

Company Drug

HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial

Fineline Cube Apr 22, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment for the...

Company Drug

Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis

Fineline Cube Apr 21, 2025

China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...

Policy / Regulatory

Shanghai Healthcare Administration Pushes for 11th Round of VBP

Fineline Cube Apr 21, 2025

Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...

Posts pagination

1 … 131 132 133 … 623

Recent updates

  • Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
  • Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
  • SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.